{"organizations": [], "uuid": "10a5c9cbfee953a5f1f28a0ba7574899ab255bf2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sirtex-medical-receives-binding-of/brief-sirtex-medical-receives-binding-offer-from-cdh-idUSFWN1ST07F", "country": "US", "domain_rank": 408, "title": "BRIEF-Sirtex Medical Receives Binding Offer From CDH", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.494, "site_type": "news", "published": "2018-05-22T16:10:00.000+03:00", "replies_count": 0, "uuid": "10a5c9cbfee953a5f1f28a0ba7574899ab255bf2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sirtex-medical-receives-binding-of/brief-sirtex-medical-receives-binding-offer-from-cdh-idUSFWN1ST07F", "ord_in_thread": 0, "title": "BRIEF-Sirtex Medical Receives Binding Offer From CDH", "locations": [], "entities": {"persons": [{"name": "varian", "sentiment": "none"}], "locations": [{"name": "sirtex", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sirtex medical ltd", "sentiment": "negative"}, {"name": "genetech", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) - Sirtex Medical Ltd:\n* ASX ALERT-SIRTEX RECEIVES BINDING OFFER FROM CDH-SRX.AX\n* HAS RECEIVED OFFER CAPABLE OF ACCEPTANCE FROM CDH GENETECH LIMITED FOR ACQUISITION OF ALL OF SHARES IN SIRTEX\n* BOARD OF SIRTEX IS CONSIDERING RELATIVE MERITS AND RISKS OF CDH PROPOSAL AND VARIAN SCHEME\n* WORLDWIDE DOSE SALES FOR PERIOD 1 JANUARY TO 30 APRIL 2018 WERE 3,755, DOWN 10.6% VERSUS PCP\n* NOW ANTICIPATES THAT FY18 UNDERLYING EBITDA WILL BE AT LOWER END OF $75-85 MILLION GUIDANCE PREVIOUSLY ISSUED\n* DIRECTORS OF SIRTEX CONTINUE TO UNANIMOUSLY SUPPORT AND RECOMMEND VARIAN SCHEME\n* SECOND HALF DOSE SALES ARE EXPECTED TO BE RELATIVELY FLAT VERSUS FIRST HALF Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-22T16:10:00.000+03:00", "crawled": "2018-05-23T15:13:36.002+03:00", "highlightTitle": ""}